More fiscal commitment is needed for research. But I think something else also is required: our attitude toward dementia needs to change.
Early success for Alzheimer’s vaccine that targets tau protein
By
John O'Connor
Dec 15, 2016
Swedish researchers have developed a vaccine that homes in on the tau protein. In fact, all but one of the 30 vaccinated patients showed a favorable immune response.
Alzheimer’s finding a real eye-opener
By
John O'Connor
Aug 01, 2015
Extra sleep can help fruit flies overcome Alzheimer’s disease-like memory problems, according to new research out of Washington University School of Medicine in St. Louis.
Straight from the gut: AI helps researchers confirm Alzheimer’s link
By
John O'Connor
Apr 24, 2024
Cleveland Clinic researchers are using artificial intelligence to confirm the link between the gut microbiome and Alzheimer’s disease.
Bill Gates sets aside $100 million for Alzheimer’s research
By
John O'Connor
Nov 14, 2017
Billionaire Bill Gates announced he will invest $50 million in the Dementia Discovery Fund. The venture capital fund links targets the disease by coordinating public and private-sector efforts.
Step up efforts to combat Alzheimer’s disease, experts urge
By
John O'Connor
May 29, 2018
Expanded efforts to understand and treat Alzheimer’s disease will be essential to unlocking its cure, according to experts at a national summit.
Focus On: There’s no one-size-fits-all way to engage residents
By
John O'Connor
Feb 13, 2020
Senior living operators use a variety of ways to describe their dementia care services, but all aim for engagement.
Olive oil may help protect against dementia, study finds
By
John O'Connor
Nov 27, 2019
An apple a day might keep the doctor away. But a diet rich in olive oil could prevent cognitive impairment.
The Senate has unanimously approved the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Act.
Combination therapy may be best Alzheimer’s bet, group claims
By
John O'Connor
Dec 13, 2018
Combination therapy likely will yield the most impressive results, according to researchers from the Alzheimer’s Drug Discovery Foundation in New York.